Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Merck will pay SciBrunch $400 million upfront for exclusive worldwide rights to SPR2015, an investigational preclinical oral KRAS G12D inhibitor. The deal has closed and carries a total potential aggregate value of $2.13 billion.
Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor. Deal grants worldwide rights to develop, manufacture, commercialize SPR2015. SciBrunch to receive USD 400 million upfront. * Milestone payments could lift total potential deal value to USD 2.13